Although in numerous early clinical analyses neither IGFR inhibitors alone nor the combination with anti-EGFR moAbs showed any promising anti-tumor activity in patients with anti-EGFR moAb-refractory mCRC [96], in a more recent randomized phase II/III study, a response to the IGF-1R inhibitor was identified by further exploratory biomarker analyses [97]. The gene discussed is IGF1R; the disease is neoplasm.